TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 177 filers reported holding TG THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,972,127 | -16.0% | 504,829 | -58.0% | 0.31% | -25.1% |
| Q3 2022 | $7,109,000 | +75.9% | 1,200,813 | +26.3% | 0.41% | +74.9% |
| Q2 2022 | $4,041,000 | +29.5% | 950,813 | +189.7% | 0.24% | +132.7% |
| Q1 2022 | $3,121,000 | +160.5% | 328,187 | +1325.1% | 0.10% | +129.5% |
| Q4 2020 | $1,198,000 | -56.5% | 23,029 | -83.7% | 0.04% | -83.4% |
| Q2 2020 | $2,754,000 | +56.4% | 141,364 | -21.0% | 0.26% | +26.8% |
| Q1 2020 | $1,761,000 | -42.9% | 178,964 | -35.5% | 0.21% | -22.9% |
| Q4 2019 | $3,082,000 | +54.7% | 277,639 | -21.7% | 0.27% | -20.3% |
| Q3 2019 | $1,992,000 | -35.1% | 354,719 | 0.0% | 0.34% | -27.0% |
| Q2 2019 | $3,068,000 | +490.0% | 354,719 | +448.1% | 0.47% | +529.7% |
| Q1 2019 | $520,000 | -21.0% | 64,719 | +29.4% | 0.07% | -72.0% |
| Q2 2018 | $658,000 | -7.3% | 50,000 | 0.0% | 0.26% | -37.0% |
| Q1 2018 | $710,000 | – | 50,000 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,890,000 | $15,800,400 | 5.14% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,360,000 | 2.75% |
| Soleus Capital Management, L.P. | 2,884,382 | $24,113,434 | 2.22% |
| M28 Capital Management LP | 216,600 | $1,810,776 | 2.08% |
| Paradigm Biocapital Advisors LP | 3,619,015 | $30,254,965 | 2.05% |
| 683 Capital Management, LLC | 1,350,000 | $11,286,000 | 0.88% |
| Parkwood LLC | 165,414 | $6,081 | 0.66% |
| Spotlight Asset Group, Inc. | 79,000 | $660,440 | 0.60% |
| Pier Capital, LLC | 392,709 | $3,283,047 | 0.53% |
| Quantum Private Wealth, LLC | 91,081 | $761,438 | 0.36% |